Status:
RECRUITING
Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
Myeloma Canada
The Leukemia and Lymphoma Society of Canada
Conditions:
Multiple Myeloma in Relapse
Multiple Myeloma, Refractory
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Patients with multiple myeloma experience a wide range of physical and psychological symptoms from the time of their diagnosis. Meanwhile, patients with aggressive lymphomas undergo unpredictable illn...
Detailed Description
In this study, the investigators will test an early palliative care intervention for patients with multiple myeloma and aggressive B cell lymphoma and their caregivers (lymphoma only) in a randomized ...
Eligibility Criteria
Inclusion
- Patient eligibility criteria:
- Inclusion criteria:
- (i) Age ≥18 years; (ii) A new diagnosis of multiple myeloma or at progression of disease necessitating a change in treatment plan, or relapsed/refractory aggressive B cell lymphoma after one prior line of therapy; (iii) Eastern Cooperative Oncology Group (ECOG) performance status 0-3; (iv) Willingness to complete symptom screening; and (v) At least one ESAS-r-plus symptom scored at ≥3 at time of recruitment.
- Exclusion criteria:
- (i) Insufficient English literacy to complete study procedures; (ii) Hematologist-determined poor cognitive status; (iii) Current palliative care team involvement at PM or elsewhere; and (iv) Not receiving ongoing follow up with malignant hematology team at PM.
- Caregiver eligibility criteria:
- Inclusion criteria:
- (i) Age ≥18 years; (ii) Caregiver of a patient with relapsed B cell lymphoma; and (iii) Willing to attend at least 1 PCC visit with the patient.
- Exclusion criteria:
- (i) Insufficient verbal and/or written English literacy to complete study procedures; or (ii) Patient not participating in study.
- Healthcare provider eligibility criteria:
- Inclusion criteria:
- (i) Specialized staff physician, fellow, clinical nurse specialist, or clinic nurse from the outpatient malignant hematology team or palliative care team at PM working clinically with patients with multiple myeloma; and (ii) Working in their clinical area for at least 12 months.
Exclusion
Key Trial Info
Start Date :
July 18 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2027
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT06485076
Start Date
July 18 2024
End Date
June 1 2027
Last Update
December 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Cancer Centre
Toronto, Ontario, Canada